SCHEMBL935303

SCHEMBL935303

OCC1CCc2cc(F)ccc2O1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.58
MLNR O43193 1/20 0.58
ADRB2 P07550 1/20 0.58
ADRB1 P08588 1/20 0.58
ADRA2A P08913 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
CHRM1 P11229 1/20 0.58
DRD2 P14416 1/20 0.58
KCNE1 P15382 1/20 0.58
ADRA2B P18089 1/20 0.58
ADRA2C P18825 1/20 0.58
CNR1 P21554 1/20 0.58
SLC6A2 P23975 1/20 0.58
NPY1R P25929 1/20 0.58
HTR2A P28223 1/20 0.58
HTR2C P28335 1/20 0.58
AVPR2 P30518 1/20 0.58
SLC6A4 P31645 1/20 0.58
ADRA1A P35348 1/20 0.58
OPRM1 P35372 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20007025 1.00 HTR1A (0.58) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL7992903 1.00 HTR1A (0.58) HTR1AMLNRADRB2ADRB1ADRA2A
Hydrochloric Acid SCHEMBL16340249 0.98 HTR1A (0.57) HTR1AMLNRADRB2ADRB1ADRA2A
Hydrochloric Acid SCHEMBL2248981 0.98 HTR1A (0.57) HTR1AMLNRADRB2ADRB1ADRA2A
Formic Acid SCHEMBL28804070 0.93 HTR1A (0.55) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL6856918 0.88 HTR1A (0.52) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL14681243 0.88 HTR1A (0.52) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL6856896 0.88 HTR1A (0.52) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL1041687 0.87 DRD2 (0.45) HTR1AMLNRADRB2ADRB1ADRA2A
SCHEMBL4932628 0.85 HTR1A (0.52) HTR1AMLNRADRB2ADRB1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102816141-A Method for preparing nebivolol racemate hydrochloride JINAN ASIA PHARMA TECH CO LTD 2012-12-12 CN claimed
WO-2010089764-A2 IMPROVED PROCESS FOR THE PREPARATION OF NEBIVOLOL HYDROCHLORIDE MSN LABORATORIES LIMITED (IN) 2010-08-12 WO claimed
CN-101020682-A Synthesis process of 6-fluoro-3, 4-dihydro-2H-1-benzopyran-2-formaldehyde UNIV ZHEJIANG (CN) 2007-08-22 CN claimed
CN-101020681-A Synthesis process of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol UNIV ZHEJIANG (CN) 2007-08-22 CN claimed
US-20070021623-A1 Novel process for preparation of nebivolol intermediates HETERO DRUGS LIMITED (IN) 2007-01-25 US claimed
EP-0334429-A1 Agents for lowering the blood pressure JANSSEN PHARMACEUTICA N.V. (BE) 1989-09-27 EP claimed
CN-110305099-B Preparation and application of nebivolol-based Smo inhibitor 东南大学 2022-11-29 CN disclosed
CN-106317006-A Preparation method of 6-fluorochromane-2-formaldehyde as nebivolol intermediate 陕西思尔生物科技有限公司 2017-01-11 CN disclosed
WO-2016185492-A1 PROCESS FOR PREPARATION OF NEBIVOLOL AND IT'S SALTS IPCA LABORATORIES LIMITED (IN) 2016-11-24 WO disclosed
EP-2265596-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2016-06-01 EP disclosed
CN-102186835-B Process for preparing nebivolol ZACH SYSTEM S.P.A. (IT) 2016-01-13 CN disclosed
EP-2528905-B1 PROCESS FOR THE PREPARATION OF NEBIVOLOL CORDEN PHARMA COLORADO INC (US) 2015-10-07 EP disclosed
EP-2346845-B1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM SPA (IT) 2015-03-25 EP disclosed
US-5824682-A Vasoconstrictive dihydrobenzopyran derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 1998-10-20 US disclosed
EP-0714396-A1 VASOCONTRICTIVE DIHYDROBENZOPYRAN DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1996-06-05 EP disclosed
WO-1995005383-A1 VASOCONTRICTIVE DIHYDROBENZOPYRAN DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1995-02-23 WO disclosed
EP-0334429-A1 Agents for lowering the blood pressure JANSSEN PHARMACEUTICA N.V. (BE) 1989-09-27 EP disclosed
EP-0145067-B1 DERIVATIVES OF 2,2'-IMINOBISETHANOL JANSSEN PHARMACEUTICA N.V. (BE) 1989-01-25 EP disclosed
US-4654362-A CARDIOVASCULAR DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 1987-03-31 US disclosed
EP-0145067-A2 Derivatives of 2,2'-iminobisethanol JANSSEN PHARMACEUTICA N.V. (BE) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021623-A1 Novel process for preparation of nebivolol intermediates ADRB2, ADRB1, ADRA1D HTR1A 94/4885MLNR 85/4885ADRB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.